Volume-weighted mean glomerular volume in spontaneously hypertensive rats treated with different doses of spironolactone

International Braz J Urol

Volumn 28, Issue 4, 2002, Pages 356-362

  Pereira, Leila Maria Meirelles ^a   Querido, Danielle L ^a   Madeira, Ágata C M ^a   Mandarim De Lacerda, Carlos A ^a  

^a STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Drug therapy; Glomerulus; Hypertension; Kidney; Rat; Spironolactone; Stereology

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRINKING WATER; SERUM ALBUMIN; SPIRONOLACTONE; TETRACYCLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE THERAPY; ARTICLE; ATTENUATION; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; GLOMERULAR STRUCTURE; GLOMERULOPATHY; HYPERTENSION; KIDNEY DISEASE; KIDNEY FUNCTION; LOW DRUG DOSE; MALE; NEPHROSCLEROSIS; NONHUMAN; ORGAN SIZE; ORGAN WEIGHT; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; STEREOLOGY; UREA NITROGEN BLOOD LEVEL; VENOUS STASIS;

EID: 0036664596     PISSN: 16775538     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Frohlich ED, Apstein C, Armstrong ML, Cohn JN, Cutler JA, Devereux RB, et al.: Target organ consequences in hypertension: pathogenesis and prevention. Hypertension. 1991; 18: I-143-I-145.
2. Kost Jr CK, Li P, Willians S, Jackson EK: Renal vascular responses to angiotensin II in conscious spontaneously hypertensive and normotensive rats. J Cardiovasc Pharmacol. 1998; 31: 854-61.
3. Delcayre C, Silvestre JS: Aldosterone and the heart: towards a physiological function? Cardiovasc Res. 1999; 43:7-12.
4. Maish B, Brilla C, Kruse T: Directions in antihypertensive treatment-our future from the past. Eur Heart J. 1995; 16 (Suppl C): 74-83.
5. Brilla CG: Aldosterone and myocardial fibrosis in heart failure. Herz. 2000; 25: 299-306.
6. Cahil MM, Kett MM, McCausland JE, Alcorn D, Bertram J: Glomerular stereology: Why, what and how to measure glomerular structure. Nephology. 1996; 2: 305-13.
7. Marcussen N: Atubular glomeruli and the structural basis for chronic renal failure. Lab Invest. 1992; 66: 265-84.
8. Fogo A, Hawkins EP, Berry PL, Glick AD, Ichikawa I: Glomerular hypertrophy in minimal change disease predicts subsequent progression to focal glomerular sclerosis. Kidney Int. 1990; 38: 115-23.
9. Irzyniec T, Mall G, Greber D, Ritz E: Beneficial effect of nifedipine and moxonidine on glomerulosclesrosis in spontaneously hypertensive rats- a micromorphometric study. Am J Hypertens. 1992; 5: 437-43.
10. Perico N, Detcheva N, Khalil EL, Remuzzi G: Cyclosporine induces glomerulosclerosis: three-dimensional definition of the lesions in rat model of renal transplant. Kidney Int. 1996; 49: 1283-88.
11. Pereira LMM, Mandarim-de-Lacerda CA: Glomerular profile numerical density per área and mean glomerular volume in rats submitted to nitric oxide synthese blockade. Histol Histopathol. 2001; 16: 15-20.
12. Gundersen HJG, Jensen EB: Stereological estimation of the volume-weighted mean volume of arbitrary particles observed on random sections. J Microsc. 1985; 138: 127-42,.
13. Sørensen FB: Stereological estimation of the mean and variance of nuclear volume from vertical section. J Microsc. 1989; 162: 203-29.
14. Mandarim-de-Lacerda CA: Estereologia e urologia: volume nuclear médio ponderado na classificação e prognóstico de tumores. Braz J Urol. 1999; 25: 286-290.
15. Mandarim-de-Lacerda CA, Pereira LMM: Renal cortical remodelling by NOs blockers in rats is prevented by ACE inhibitor and calcium channel blocker. J Cell Mol Med. 2001; 5: 276-83.
16. Zar JH: Biostatistical analysis. Upper Saddle River, Prentice-Hall, 1999; p. 663.
17. Sharp PE, La Regina MC: The laboratory rat. Boca Raton, CRC Press, 1998; p. 214.
18. Wilcox CS: Evaluation of Kidney Function: Biochemical and Nuclear Medicine Tests. In: Tischer CC, Wilcox CS (eds.). Nephrology & Hypertension. Philadelphia, Lippincott Williams & Wilkins, 1999; pp. 19-22.
19. Lacolley P, Safar MR, Lucet B, Ledudal K, Labat C, Benetos A: Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats. J Am Coll Cardiol. 2001; 37: 662-7.
20. Zannad F: Angiontensin-converting enzyme inhibitor and spironolactone combination therapy. New objectives in congestive heart failure treatment. Am J Cardiol. 1993; 71: 24A-39A.
21. Ramires FJA, Sun Y, Weber KT: Myocardial fibrosis associated with ALDO or angiotensin II administration: attenuation by calcium channel blockade. J Mol Cell Cardiol. 1998; 30: 475-83.
22. Sadoshima J, Izumo S: Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype. Cir Res. 1993, 73: 413-23.